A retrospective cohort study of more than a half million new users of hormonal contraception shows that drospirenone is associated with a higher risk of thrombotic events than contraceptives containing low-dose estrogen.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.